Related Experiment Video

Updated: Nov 29, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.6K

Partial responses to ibrutinib in Waldenström macroglobulinaemia - good enough?

Umberto Vitolo1, Mattia Novo1, Elisa Santambrogio1

  • 1Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy.

British Journal of Haematology
|November 18, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
BTK inhibitorsWaldenstrom macroglobulinemiaibrutinibprogression-free survivalresponse

More Related Videos

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.0K

Related Experiment Videos

Last Updated: Nov 29, 2025

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.6K
A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

8.0K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

338
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
338

Articles linked to this work by shared authors, journal, and citation graph.

Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

Blood·2026

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

HemaSphere·2026

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia·2026

Infections and CAR-T cells for the treatment of lymphoid malignancies: a narrative review.

Frontiers in medicine·2026

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

The Lancet. Haematology·2026

Functional assessment of inherited myeloid neoplasm-associated SAMD9L germline variants via Monoallelic CRISPR modelling.

British journal of haematology·2026

First-line hetrombopag combined with immunosuppressive therapy for paediatric severe aplastic anaemia: A prospective randomized controlled trial.

British journal of haematology·2026

Sickle cell disease and commercial aviation. A retrospective analysis of in-flight and pre-flight medical events.

British journal of haematology·2026

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.

British journal of haematology·2026

Autoimmune neutropenia in children: Test cells versus beads and a role for pro-LL-37 and absolute neutrophil count.

British journal of haematology·2026

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.

British journal of haematology·2026

A Microfluidic Platform for Studying Roles of Mechanical Compression in Tumor-Immune Cell Interactions in a 3D Extracellular Matrix.

Journal of visualized experiments : JoVE·2026

Nanobodies specific for Vβ11 enable detection and noninvasive imaging of antigen-specific T cells in vivo.

Journal of immunology (Baltimore, Md. : 1950)·2026

Organization from cell to tissue derived delivery systems for immunotherapy.

Materials today. Bio·2026

Corrigendum to "Disappearance of the Defining Organized Ultrastructural Lesion in Chronic Lymphocytic Leukemia-Associated Monoclonal Immunotactoid Glomerulopathy After Ibrutinib Therapy" [Kidney International Reports Volume 11, Issue 8, August 2026, 106643].

Kidney international reports·2026

Proteomic profiling and comparative hemotoxicity of Gloydius brevicaudus and Deinagkistrodon acutus venoms: insights into functional convergence.

The journal of venomous animals and toxins including tropical diseases·2026

Correction: The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us